{ "docId": "019dd923-622c-750b-8b9a-2a2468219173", "docSlug": "ce565b841c40", "documentTitle": "Nevro Corp. (NVRO)", "authorId": "58_Scorpion_Capital", "authorName": "Kir Kahlon", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2021-01-07 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 190, "pageCount": 239, "prevPage": 189, "nextPage": 191, "slideType": "testimonial", "function": "expose_contradiction", "density": "overcrowded", "nDataPoints": 0, "notes": "The slide uses a 'villain critique' style by highlighting the defection of key opinion leaders (KOLs) from the subject company to a competitor.", "elementsJson": [ "headline_text", "paragraph", "bullet_list", "quote_block", "footnote" ], "metadataConfidence": 0.95, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/190", "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173", "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-190", "components": [ { "bbox": null, "kind": "callout", "text": "In a space driven by the trendy new device, the color suggests that Saluda is the \"new Nevro\" while Nevro is yesterday's fad.", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-3f3d-76db-b347-0e30dbb51590", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.05, "w": 0.88, "x": 0.06, "y": 0.66 }, "kind": "list", "text": "A high volume implanter who uses some Nevro stated that Saluda has “the best data ever” and that it “beats Nevro’s data” while another called it “really cool.”", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "500e2336-5e69-438e-b96f-cc86be64d55c", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.05, "w": 0.88, "x": 0.06, "y": 0.51 }, "kind": "list", "text": "One of Nevro’s highest volume implanters and speakers states he and his colleagues are “enthusiastically waiting” and that it “looks very exciting.”", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "a3730c10-49a2-4806-baa8-11d03de63b78", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.05, "w": 0.88, "x": 0.06, "y": 0.35 }, "kind": "list", "text": "A Saluda investigator, previously one of Nevro’s highest volume implanters, said he’s “never seen anything” as good as Saluda", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "fc433f78-6b42-4b6b-bb9d-18a2d71dc911", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.88, "x": 0.06, "y": 0.09 }, "kind": "paragraph", "text": "14. Unknown to most investors, Nevro faces an impending, disruptive competitive threat within 6 to 12 months: Saluda Doctor excitement about Saluda reinforces the severity of the threat described by Nevro’s ex-executives and competitors.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "ec7723c5-0338-43f6-b761-da1ed9ef0ca1", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.1, "w": 0.83, "x": 0.11, "y": 0.72 }, "kind": "quote", "text": "“No one waveform is perfect for a patient. That’s what Saluda is trying to do. It’s very cool. It’s the best tonic device out there. It’s the best tonic data ever. Their data beats Nevro’s data. I hope Medtronic or someone buys them because it would give them a competitive advantage.” – High volume implanter and Nevro user", "attrs": null, "subkind": "testimonial", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "2c64060e-d4e5-439c-adaa-0abc2a17b623", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.83, "x": 0.11, "y": 0.83 }, "kind": "quote", "text": "“Saluda is really cool. The device has an opportunity to be very efficient. I’m optimistic about it.” – High volume implanter", "attrs": null, "subkind": "testimonial", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "732f5905-edbe-4d79-8c2f-a746a6ab50a9", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.06, "w": 0.83, "x": 0.11, "y": 0.57 }, "kind": "quote", "text": "“I guess we’re enthusiastically waiting for Saluda to come out and to see if that’s a game changer. Saluda overall looks very exciting and it makes sense.” – KOL and Nevro speaker", "attrs": null, "subkind": "testimonial", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "b8f94417-ddf0-43fe-a309-b77c3ce0d337", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.08, "w": 0.83, "x": 0.11, "y": 0.41 }, "kind": "quote", "text": "“I was on Saluda’s trial and it’s published so the data is all out there. It was very good, like really good. I’d never seen anything like it. And these were normal patients. Real patients, not cherry-picked.” – KOL and previously a high volume Nevro implanter", "attrs": null, "subkind": "testimonial", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "c1ee230b-cff4-48f9-b090-ea82162c0e1a", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "\"I was on Saluda’s trial and it’s published so the data is all out there. It was very good, like really good. I’d never seen anything like it. And these were normal patients. Real patients, not cherry-picked.\" — KOL and previously a high volume Nevro implanter; \"I guess we’re enthusiastically waiting for Saluda to come out and to see if that’s a game changer. Saluda overall looks very exciting and it makes sense.\" — KOL and Nevro speaker; \"No one waveform is perfect for a patient. That’s what Saluda is trying to do. It’s very cool. It’s the best tonic device out there. It’s the best tonic data ever. Their data beats Nevro’s data. I hope Medtronic or someone buys them because it would give them a competitive advantage.\" — High volume implanter and Nevro user; \"Saluda is really cool. The device has an opportunity to be very efficient. I’m optimistic about it.\" — High volume implanter", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd953-3f3d-76db-b347-123447971499", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.2, "x": 0.06, "y": 0.96 }, "kind": "source-note", "text": "Source: Consultation calls with experts", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "0aeff59f-bbf8-4b25-a571-02816b9e7a59", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.06, "y": 0.04 }, "kind": "title", "text": "Scorpion Capital | Nevro (NYSE: NVRO)", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "c8bd9d35-ddbb-4934-95cb-a98d24fb8eb1", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }